HYNIC-PSMA is a PSMA-targeting peptide conjugated to a HYNIC chelator, facilitating coordination of technetium or related metals for tracer design. The peptide moiety provides high-affinity binding, while HYNIC offers versatile radiolabeling chemistry. Researchers assess labeling efficiency, stability, and receptor-binding properties. Applications include radiometal-peptide conjugate studies, PSMA-epitope mapping, and imaging-ligand optimization.
HYNIC-PSMA is a synthetic peptide conjugate that combines a prostate-specific membrane antigen (PSMA)-targeting peptide with hydrazinonicotinamide (HYNIC), a versatile bifunctional chelator. As a member of the peptide-chelator conjugate class, HYNIC-PSMA is engineered for high-affinity recognition of PSMA, a transmembrane glycoprotein abundantly expressed in prostate cancer cells and certain neovasculature. The HYNIC moiety facilitates efficient radiolabeling with technetium-99m and other suitable radionuclides, making this compound highly relevant to molecular imaging, targeted probe development, and biochemical studies of PSMA-mediated processes. Its modular structure and tunable properties support a range of research applications in oncology, chemical biology, and radiopharmaceutical sciences.
Targeted imaging probe development: HYNIC-PSMA serves as a foundational scaffold for the design and synthesis of radiolabeled imaging agents targeting PSMA-expressing tissues. By exploiting the high affinity and specificity of the PSMA-binding peptide, researchers can efficiently generate molecular probes for preclinical imaging studies. The HYNIC chelator allows for robust coordination of diagnostic radionuclides, facilitating the development of single-photon emission computed tomography (SPECT) tracers and related molecular imaging tools.
Radiolabeling method optimization: The compound is widely utilized in the optimization and validation of radiolabeling protocols, particularly for technetium-99m. Its stable and efficient chelation chemistry enables researchers to refine labeling conditions, assess radiochemical yields, and evaluate in vitro and in vivo stability. This application is critical for the advancement of radiopharmaceutical development, ensuring reproducibility and reliability in the preparation of PSMA-targeted imaging agents.
PSMA-targeted ligand research: As a model PSMA ligand, HYNIC-PSMA is employed in binding affinity studies, receptor mapping, and competitive inhibition assays. Its well-characterized structure allows for detailed investigations into PSMA-ligand interactions, supporting the rational design of next-generation targeting peptides and the elucidation of structure-activity relationships. These studies contribute to a deeper understanding of PSMA biology and its role as a biomarker in cancer research.
Biodistribution and pharmacokinetic analysis: Researchers use HYNIC-PSMA in preclinical models to evaluate tissue distribution, clearance kinetics, and target-to-background ratios of PSMA-targeted probes. Quantitative biodistribution studies employing radiolabeled derivatives provide essential data on organ uptake, excretion pathways, and specificity, informing the selection and optimization of lead compounds for further development.
Conjugation and chemical modification studies: The modular design of HYNIC-PSMA enables its use as a building block for the synthesis of multifunctional conjugates. Researchers can investigate the effects of linker chemistry, multimerization, or additional functionalization on PSMA targeting and chelation efficiency. Such studies are instrumental in advancing the field of targeted molecular diagnostics and expanding the chemical toolbox for site-specific labeling strategies.
4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More